PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22890083-1	2012	OBJECTIVE: To compare the assessment of response and prognosis of patients to sorafenib treatment by the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP).	Sorafenib	78-87	angiotensin I converting enzyme	Homo sapiens	215-244	
27167344-0	2016	Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.	Sorafenib	57-66	angiotensin I converting enzyme	Homo sapiens	0-29	
27167344-2	2016	We hypothesized that DCP (des-gamma-carboxy prothrombin), a prothrombin precursor produced in HCC, might be one of the reasons linked to the low efficacy of Sorafenib.	Sorafenib	157-166	angiotensin I converting enzyme	Homo sapiens	26-55	
21347197-0	2010	Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases.	Sorafenib	145-154	angiotensin I converting enzyme	Homo sapiens	83-112	
22116493-1	2011	OBJECTIVES: The aim of this study was to investigate the relationships between early changes in the tumor markers alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP), and antitumor response in the early period following administration of sorafenib in patients with advanced hepatocellular carcinoma (HCC).	Sorafenib	250-259	angiotensin I converting enzyme	Homo sapiens	142-171